Article
NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
Pharmacogenetics and genomics - 1 Jul 2018
Suvichapanich Supharat, Fukunaga Koya, Zahroh Hilyatuz, Mushiroda Taisei, Mahasirimongkol Surakameth, Toyo-Oka Licht, Chaikledkaew Usa, Jittikoon Jiraphun, Yuliwulandari Rika, Yanai Hideki, Wattanapokayakit Sukanya, Tokunaga Katsushi
Abstract excerpt
BACKGROUND: NAT2 slow acetylator is a confirmed risk of anti-tuberculosis drug-induced liver injury (ATDILI). However, NAT2 ultra-slow acetylators, a new refinement among NAT2 slow acetylators, have been recently proposed. The patients with NAT2 genotypes of *6A/*6A, *6A/*7B and *7B/*7B are referred to in this group. OBJECTIVE: We aim to prove an association of the NAT2 ultra-slow acetylators with the risk of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
